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ABSTRACT
Introduction: Bisphosphonates are becoming
a common treatment for osteoporosis particularly after
discovery of the association between hormone
replacement therapy and increased risk of breast
cancer. As osteoporosis develops with age, treatment
is a long-term intervention. Randomised control trials
typically have limited follow-up times, which restricts
investigation of the effects of the drugs on risk of
primary cancers. A few observational studies have
demonstrated a reduced risk of breast cancer and
possibly of endometrial cancer in bisphosphonate
users. Two epidemiological studies have studied the
effect of the drugs on oesophageal cancer but did not
reach any deﬁnite conclusions. So far, no effects on
colorectal and stomach cancer have been shown. This
study will investigate the association of
bisphosphonates with risks of the 10 most common
primary cancers.
Methods and analysis: A series of nested
caseecontrol studies will be based on the general
population using records from 660 UK general
practices within the QResearch Database. Cases will be
patients with primary cancers diagnosed between
1996 and 2011. Each case will be matched by age, sex,
practice and calendar year to ﬁve controls, who are
alive and registered with the practice at the time of
diagnosis of the case. Exposure to bisphosphonates
will be deﬁned as at least one prescription during the
study period. For the most common cancers with
substantial numbers of observations, the effect of the
duration of the treatment and different types of
bisphosphonates will be studied. Conditional logistic
regression will be applied to produce ORs adjusted for
smoking status, socioeconomic status, ethnicity,
cancer-speciﬁc co-morbidities and use of other
medications.
INTRODUCTION
Osteoporosis among the older people is
a major problem leading to increased
mortality and morbidity and high costs for
health services. Thirty-ﬁve per cent of the
European population aged 50 years and over
suffer from fractures caused by osteoporosis.
1
Between 1980 and 1990, the use of hormone
replacement therapy (HRT) was considered
a preventive measure for postmenopausal
osteoporotic fractures in women but, after
a Women’s Health Initiative trial report
about increased risk of breast cancer, use of
HRT fell signiﬁcantly.
2
As a treatment for postmenopausal osteo-
porosis, bisphosphonates were introduced in
the 1990s, and prescribing of them has
increased substantially and continually. HRT
(raloxifene) and the use of calcitonin and
strontium ranelate
3 are still considered to be
options for the treatment of osteoporosis, but
according to the UK National Institute for
Health and Clinical Excellence guidelines,
45
recommending bisphosphonates as a ﬁrst-
line therapy for osteoporosis bisphospho-
nates have become the most commonly
prescribed drug.
The proportion of the female population
in the UK eligible for treatment varies
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ARTICLE SUMMARY
Article focus
- Bisphosphonate use.
- Effect on incidence of cancer.
- Designing a study.
Key messages
- Series of caseecontrol studies will examine
possible associations between use of bisphosph-
onates and risk of cancer.
- Effect of dose, duration and different types of
drug will be investigated.
- Results will be adjusted for a number of
confounders.
Strengths and limitations of this study
- Large sample size.
- Based on the general populations.
- Based on routinely collected data.
- Prescriptions not actual use.
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6 The drugs
increase bone mass and reduce the risk of fracture, but
these effects become signiﬁcant only after 6e36 months
of use depending on the type of drug.
7 Bisphosphonates
bind to bone and, depending on type, can be released
for up to ten more years after treatment ceases.
8
The ﬁrst use of bisphosphonates in the 1970s was in
oncology. They were used for the treatment and
prevention of skeletal disorders associated with multiple
myeloma and bone metastases from breast, prostate,
lung and kidney cancers and other solid tumours.
Bisphosphonates have also been used for glucocorticoid-
induced osteoporosis.
7
There is preclinical evidence for the anti-tumour
effects of bisphosphonates because of their anti-resorp-
tive properties.
9 Bone is a good environment for tumour
cells because of a number of growth factors. Osteoclasts
affect release of soluble growth factors and so promote
tumour cells. Bisphosphonates accumulated in bones
inhibit osteoclast-mediating bone resorption with
signiﬁcant clinical effect. The drugs also demonstrate
anti-tumour effects in vitro by inhibiting angiogenesis
(adhesion, invasion and proliferation) and inducing
apoptosis. The cancers studied in vitro were breast,
prostate, myeloma, pancreatic and osteosarcoma.
10
These preclinical studies, however, were conducted with
concentrations far higher than those used for treating
patients with bone metastates.
11
Although the anti-tumour properties of bisphospho-
nates are being considered for prevention of bone
metastases and a few clinical trials have demonstrated
the efﬁcacy of bisphosphonates in women with early-
stage breast cancer,
12 they have been little studied in
relation to the development of other primary cancers.
Four epidemiological studies concentrating on breast
cancer have shown positive effects for bisphosphonates:
32% RR reduction in postmenopausal women (HR 0.68,
95% CI 0.52 to 0.88),
13 33% decreased risk in current
users, women aged 20e69 years (OR 0.67, 95% CI 0.51
to 0.89),
14 39% risk reduction in patients taking
bisphosphonates for at least 1 year (OR 0.61, 95% CI
0.50 to 0.76)
15 and 47% risk reduction after start of
alendronate (HR 0.53, 95% CI 0.38 to 0.73) and 20% for
etidronate (HR 0.80, 95% CI 0.73 to 0.89).
16 A study
looking at the risk of endometrial cancer has also
shown a 30% decrease associated with bisphosphonate
use, but it was not statistically signiﬁcant (OR 0.7, 95%
CI 0.4 to 1.2).
17
Because bisphosphonates are associated with short-
term gastrointestinal adverse effects,
8 an adverse effect
on risk of oesophageal cancer might be expected. The
ﬁrst publication about the association was from the US
Food and Drug Administration Adverse Event Reporting
System, which listed 23 cases of oesophageal cancer in
users of oral alendronate between 1995 and 2008.
18 A
further observational study, based on 13678 bisphosph-
onate users matched to 27365 non-users, identiﬁed 37
oesophageal cancers and 48 gastric cancers and showed
reduced risks for oesophageal and gastric cancers
(HR 0.35, 95% CI 0.14 to 0.85 and HR 1.23, 95% CI 0.68
to 2.22, respectively).
19
A caseecontrol study looking at 2954 cases of oeso-
phageal, 2018 cases of gastric and 10641 cases of colo-
rectal cancers, based on the General Practice Research
Database, demonstrated a 30% increased risk of oeso-
phageal cancer in patients with at least one prescription
for bisphosphonates (OR 1.30, 95% CI 1.02 to 1.66)
20
but did not ﬁnd a signiﬁcant effect on risk of gastric or
colorectal cancers (OR 0.87, 95% CI 0.64 to 1.19 and OR
0.87, 95% CI 0.77 to 1.00, respectively). A cohort study
based on the General Practice Research Database did
not ﬁnd any signiﬁcant association between bisphosph-
onate use and risk of gastric or oesophageal cancers
21
(combined HR 0.96, 95% CI 0.74 to 1.25, for oesopha-
geal cancer only HR 1.07, 95% CI 0.77 to 1.49). As for
colorectal cancer, an Israeli study showed a signiﬁcantly
decreased risk in patients taking bisphosphonates for
more than a year (RR 0.50, 95% CI 0.25 to 0.67).
22 A
Danish study looked at gastrointestinal cancers and
reported an excess risk of oesophageal cancer associated
with use of alendronate (HR 2.10, 95% CI 1.01 to 4.35)
and etidronate (HR 1.99, 95% CI 1.24 to 3.18) and
a possible protective effect of higher doses for colorectal
cancer (HR 0.29, 95% CI 0.14 to 0.62).
23 So far no
epidemiological studies have investigated associations
with risks of other common cancers for bisphosphonate
users. A few randomised controlled trialsdthe longest
for up to 10 years
24e26dhave studied the effect of the
drugs on skeletal properties and general adverse effects,
but none of them have considered cancer as a conse-
quence of osteoporotic therapy. A cohort study in
patients treated for osteoporosis including bisphospho-
nates is currently enrolling participants to explore
a number of adverse events in the next 5 years.
27 This is
the only study where malignancies form part of the
secondary outcome measures.
Our aim is to examine possible associations between
use of bisphosphonates and risk of a range of common
cancers in a large community sample, including the
effect of dose, duration and type of drug.
METHODS AND ANALYSIS
Sample selection
This will be a study using the QResearch primary care
research database, which consists of routinely collected
data from general practitioner clinical computer
systems. The contributing practices, which comprise
around 7% of all UK general practices, use the Egton
Medical Information System. QResearch is one of the
largest general practice databases, containing anony-
mised clinical records for over 13 million patients
registered with 660 UK general practices. The informa-
tion recorded on the database includes patient demo-
graphics (year of birth, sex, socio-demographic data
derived from UK census 2001), characteristics (height,
weight, smoking status), clinical diagnoses, symptoms
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tions). Detailed analyses, including age and sex distri-
bution, birth rates and death rates, have been
undertaken and have shown good correspondence with
other sources
28 and demonstrated the accuracy and
completeness of the data.
29
An open cohort of patients will be identiﬁed, 30 years
or older, registered with the study practices during the
study period, between 1 January 1996 and 1 July 2011.
Temporary residents will be excluded. Cases will be
incident cases of cancer identiﬁed during the study
period, and these will include the 10 most common
cancers. Cases with any previous cancer diagnosis will be
excluded. Cases with secondary cancers (READ codes:
B56, B57, B58) will be excluded. The right censor date
will be the earliest of the following: date of diagnosis of
cancer, date of death, date of leaving the practice, date
of the latest download of data, the study end date.
Cases and controls
Each case will be matched to ﬁve controls, who are alive
and registered with the practice at the time of diagnosis
of the case. Controls will be matched on age, sex, prac-
tice and calendar year using incidence density sampling.
Controls will be allocated an index date, which is the
date on which their matched case was ﬁrst diagnosed
with cancer. Controls with a diagnosis of any cancer
before the index date will be excluded.
Cases and controls with a record of mastectomy before
their ﬁrst prescription of bisphosphonates will be
excluded since this treatment is likely to indicate
a previous diagnosis of breast cancer with further bone
metastases. For breast cancer, only female patients will be
included. All patients with Paget’s disease will be
excluded as the treatment for this condition is admin-
istered in higher doses and for much longer periods
(typically 2 weeks for osteoporosis against 6 months for
Paget’s). Patients with prescriptions for the bisphosph-
onates licensed not for osteoporosis but for malignan-
cies (zoledronic acid, clodronate and daily use of
ibandronate) will also be excluded.
For the main analysis, cases and controls will be
included if they have complete records for at least
2 years before the index date. A subset of cases and
controls with at least 6 years of records will be used for
further analyses.
The risks of any cancer and of the 10 most common
cancers will be determined for patients prescribed
bisphosphonates and compared with the risks for
patients not prescribed these drugs. The ‘most common’
cancers have been selected because they have this status
in the UK.
30 They are breast cancer (women, B34),
prostate cancer (men, B46), lung cancer (B22), colo-
rectal cancer (B13, B14), haematological malignancies
(B6), bladder cancer (B49), melanoma (B32), gastric
cancer (B11), pancreatic cancer (B17) and oesophageal
cancer (B10). As osteoporosis might be an early
symptom of possible myeloma, it will be analysed
separately from lymphoma and leukaemia. The
commoner female cancers (ovary (B44), uterus (B43)
and cervix (B41)) will also be considered.
Interventions
Exposure to drugs for osteoporosis will be determined
based on all prescriptions for bisphosphonates and other
drugs before the index date (date of diagnosis or equiv-
alent date for controls) within the observation period
(from the date of entry into QResearch to the index
date). The bisphosphonates to be included are identiﬁed
in the British National Formulary section 6.6.2 as treat-
ment for osteoporosis
3: alendronate (5e10 mg daily or
70 mg weekly), etidronate (400 mg daily for 14 days in
90-day cycles), ibandronate (150 mg a month or intra-
venous 3 mg/3 months) and risedronate (5mg daily).
The cumulative exposure to bisphosphonates will be
assessed by extracting duration of the prescribed days’
supply and summarising it for each patient. For drugs
prescribed in cycles, the length of a cycle will be
considered as duration of a prescription, for example,
etidronate prescription for 2 weeks will be assessed as
a 90-day prescription duration. The same approach will
be applied to intravenous infusion, considering the
recommended interval between injections as the dura-
tion of a prescription (eg, 3 months for ibandronate).
The cumulative exposure to bisphosphonates will be
estimated by extracting the duration for every prescrip-
tion, and for groups of prescriptions with inter-
prescription gaps of <60 days, overall course times will
be calculated from the start of the ﬁrst prescription to
the end of the last prescription.
As bisphosphonates can be released for months after
a treatment, total exposure to bisphosphonates will be
estimated as the time between the ﬁrst prescription and
the end time for the last prescription.
Because bisphosphonates and other osteoporosis
treatment drugs are prescribed for years, long-term users
andshort-termusers willbedistinguished,astreatmentof
the latter might have been for accidental or clinical frac-
tures or for better integration of biomaterial or implants.
The effect of bisphosphonates on treating fractures
varies from 6 to 36 months, for example 12 months for
risedronate and 24 months for alendronate.
7
There are three regimens for bisphosphonate use:
daily, once weekly and once monthly. Daily use has been
shown to have lower adherence than weekly use.
31
Another reason for investigating regimens is that,
particularly for gastrointestinal organs, there might be
a marked difference between the effects of daily and
weekly exposure to bisphosphonates, with associated
effects on risks for oesophageal, gastric and colorectal
cancers.
Bisphosphonate use will be categorised in a number of
ways. The main analyses will compare patients having no
prescriptions for the drugs with patients with at least one
prescription for any bisphosphonate. The effect of
prescribing for short-term (<12 months) and long-term
(at least 12 months) periods will then be analysed, as well
as the effect of regimen: daily or weekly/monthly.
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further analyses will be run for the cumulative exposure
(cumulative duration of all prescriptions) and the
exposure time to bisphosphonate (the time period
between the ﬁrst prescription and the end time for the
last prescription). The subset of data with at least 6 years
of records will be analysed using following catego-
risations: no use, <180 days, 180 days up to 12 months,
12e24 months and $25 months. A test for trend will be
performed using the actual number of months.
Timing will be categorised as: no use before diagnosis,
used within 1e2 years before the index date and used
>2 years before the index date. The interaction of
timing and terms of treatment will also be examined,
categorised as: no use before diagnosis; used within
1e2 years before the index date, short-term use; used
within 1e2 years before the index date, long-term use;
used >2 years before the index date, short-term use and
used >2 years before the index date, long-term use.
If there are any variations in dose of bisphosphonates,
it will be categorised as low (<67% of dose recom-
mended by dose) and normal/high (>66% of recom-
mended dose).
The two main types of bisphosphonatesdsimple
bisphosphonates (etidronate) and nitrogen contai-
ning
7dwill be analysed as there are two different
mechanisms of action for the drugs. If there are
sufﬁcient numbers, the data will also be analysed by
individual drug.
Because prescriptions in the year before the index
date might be associated with an early symptom of
cancer before a recorded diagnosis, sensitivity analyses
ignoring all prescriptions in the last year before the
index date will be run. The results from these analyses
will highlight any attenuation of the protective effects of
bisphosphonates or any increases in magnitudes of
harmful effects. A sensitivity analysis on the main analysis
will also be run, deﬁning the use of bisphosphonates as
at least two prescriptions within the observation period.
The analyses will be repeated on a subgroup of patients
with at least 6 years of records to estimate the long-term
effect of bisphosphonate use.
The other drugs for osteoporosis to be included are
strontium ranelate, raloxifene and calcitonin. As there
will not be enough observations to analyse each drug
individually, they will be combined and included in the
analyses as other treatment for osteoporosis. A patient
will be considered as a user if they have at least one
prescription of any of those drugs in their records before
the index date.
Confounding factors
All the analyses will include potential confounders which
are established as risk factors for cancer: body mass
index
32 (continuous variable, at the date closest to 1 year
before the diagnosis and recorded before the
index date); smoking status
33 (current smokerdlight
(1e9 cigarettes/day), medium (10e19 cigarettes/day)
and heavy ($20 cigarettes/day); ex-smoker and
non-smoker); excessive alcohol consumption
34 using
Read codes for alcohol status (only if it is a signiﬁcant
confounder for the sample); socioeconomic status
35
(Townsend score in ﬁfths) and ethnicity
36 (Caucasian,
AfricaneAmerican, Asian and other). The analysis will
also adjust for osteoporosis history,
37 including diagnosis
of osteoporosis or osteopenia or previous fractures,
use of drugs increasing risk of fracture (systemic
corticosteroids and proton pump inhibitors
38), use of
anti-inﬂammatory drugs
39 (traditional non-steroidal,
cyclooxygenase 2 inhibitors and aspirin)
40 and use of
vitamin D.
41
Co-morbidities which affect risks of cancer will also be
included: rheumatoid arthritis
42 for any cancer; hyper-
tension
43 for uterine cancer and diabetes and glucose
intolerance for pancreatic,
44 uterine
45 and colorectal
46
cancers. Analyses of colorectal, oesophageal, gastric and
pancreatic cancers will be adjusted for gastrointestinal
disorders
47 if diagnosed before the ﬁrst use of
bisphosphonates or 12 months before the index date,
whichever is earlier: upper gastrointestinal disease
(dysphagia, oesophagitis, gastrooesophageal reﬂux
disease, hiatus hernia, oesophageal ulcers, Barrett’s
oesophagus, gastritis, duodenitis, peptic ulcers,
dyspepsia); Crohn’s disease, ulcerative colitis, and
pancreatitis. Bladder cancer analyses will include renal
impairment
48 (diagnostic code for chronic kidney
disease) if diagnosed before the ﬁrst use of bisphosph-
onates or 12 months before the index date, whichever is
earlier. Breast cancer analyses will also include previous
benign breast disease (ﬁbrocystic disease, intraductal
papilloma or ﬁbroadenoma).
49 The results will also be
adjusted for family history of cancer
50 (this will vary
according to the cancer under consideration) if
recorded 6 months before the index date. This is to
reduce family recall bias as cases are more likely
to report a family history of cancer around the time of
diagnosis.
51
Because use of some drugs might be associated with
increased risk of some cancers, use of HRT
52 and oral
contraceptives
53 for breast, uterine, ovarian and cervical
cancers will also be included. Use of acid suppression
drugs
54 (including H2 antagonists (BNF 1.3.1), proton
pump inhibitors (BNF 1.3.5) and antacids (BNF 1.1.1))
will be added for gastrointestinal cancer analyses. If
there are enough observations, use of those drugs will be
categorised by the number of prescriptions within the
observation period: none, fewer than 12 prescriptions,
12e24 prescriptions, 25e48 prescriptions and >49
prescriptions.
Statistical analysis
Conditional logistic regression will be used to estimate
OR with 95% CIs for cancer of any site and each of the
10 most common cancers and three additional female
cancers and their matched controls. The initial analysis
model will determine the unadjusted ORs for each
cancer associated with bisphosphonate prescriptions. A
multivariable model will determine the OR for each
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adjusted for the potential confounding effects of the
variables listed above.
As body mass index, smoking status and alcohol
consumption may be important confounders but have
non-negligible numbers of missing data, multiple
imputation will be used to impute the missing values.
Ten imputed data sets will be created. Index year, case/
control status, years of records, potential confounders
and exposure to bisphosphonates and other drugs will
be included. For comparison, analyses with missing data
treated as separate categories will also be carried out.
Stata V.11 will be used for all the analyses. A 1%
signiﬁcance level will be used to account for the multiple
outcomes.
Sample size calculation
As different types of cancer may have different risks
associated with bisphosphonate use, analyses will require
number of cases to relate to each type of cancer. All
available data from QResearch will be used. Our calcu-
lations are based on the exposure to bisphosphonates in
the proposed data extraction for 6.8% of women and
1.8% of men. For non-gender-speciﬁc cancers, the total
proportion of users is estimated as 4.2%. To detect an
OR of 0.87 (for colorectal or stomach cancers
20), 22322
cases will be needed. To detect an OR of 1.3 (for oeso-
phageal cancer
20), 5208 cases will be needed. To detect
an OR of 0.70 (for breast
14 or uterus
17 cancers), 2382
female cases will be needed. For prostate cancer, to
detect 30% increase (or decrease) in risk, 11773 (or
8686) male cases will be needed. For other cancers,
a detection of 30% risk decrease will require 3785 cases.
All calculations are done for matched sets of cases and
controls, with 4.5 matched controls per case, an esti-
mated coefﬁcient for exposure between matched cases
and controls of 0.2, a power of 80% and a signiﬁcance
level of 1%.
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